Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm

Mali, Yasmin P.; Schultze, R.; Wladis, Edward J.

doi:10.1080/01676830.2017.1337164

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nezaznamenali sme rozdiel v osmolarite slzného filmu podobne ako iní autori [16], vyvetlením zrejme bude komplexnosť stavu a chronicky zmenená regulácia u suchého oka u pacientov s hemi-alebo blefarospazmom. Samotná denervácia slznej žľazy BT-A zrejme nestačí na zmenu osmolarity.…”

Section: Diskusiaunclassified

The Effect of Botulinum TOxin Application if Neuro-Ophthalmological Indications on the Results of Schirmer’s Test and Tear Osmolarity

Žiak

Halička

Kapitánová

et al. 2019

CSO

View full text Add to dashboard Cite

Botulinum toxin type A (BT-A) is used in the treatment of neuroophthalmologic disorders such as essential blepharospasm and facial hemispasm for more than 20 years. Although the long-term effect of repeated application of the BT-A was confirmed, the BT-A effect on tears production and retention is not clear. In our work we investigated whether applied BT-A in patients with blepharospasm and hemifacial spasm affect tears production. Tears quality was measured with Schirmer’s and tear osmolarity test during neuro-ophthalmologic diseases treatment, which was evaluated before and 14 days after application of BT-A (Botox inj, Allergan, Irvine, USA) into the orbicularis oculi muscle. BT-A doses of 16-18 U with unilateral and 32 to 36 U bilateral applications were used. The mean tear production in Schirmer’s test before BT-A application was 8.38 ± 0.63 mm, and 2 weeks after BT-A application was 7.12 ± 0,6 mm (n = 50). Tear osmolarity was 305.4 ± 9.2 mOsm before BT-A application, and 2 weeks after BT-A application it was 305.2 ± 8,6 mOsm (n = 13). We found significant difference between two groups in tear quantity (p < 0.012), but not quality (p > 0.05). Application of the BT-A reduced the amount of tears measured by Schirmer’s test. These results confirm rational basis of the empirical clinical experience where an artificial tears substitution is recommended for patients with neuro-ophthalmologic disorders treated by BT-A.

show abstract

Section: Diskusiaunclassified

The Effect of Botulinum TOxin Application if Neuro-Ophthalmological Indications on the Results of Schirmer’s Test and Tear Osmolarity

Žiak

Halička

Kapitánová

et al. 2019

CSO

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6][7] Although the efficacy and side effects of BTX injection for HFS treatment have been well established, the effect of BTX-A on dry eye signs and symptoms is still controversial. 5,[8][9][10][11][12][13][14][15][16][17] Furthermore, there are some studies that investigated the association between dry eye and facial dystonia. [18][19][20][21] Only limited studies compared dry eye between affected eye and contralateral non-affected eye in the hemifacial spasm patients.…”

Section: Introductionmentioning

confidence: 99%

Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A

Jariyakosol

Uthaithammarat

Chatwichaikul

et al. 2021

OPTH

View full text Add to dashboard Cite

Purpose To assess the impact of botulinum toxin type A (BTX-A) on signs and symptoms of dry eye (DE) in affected eye of hemifacial spasm (HFS) patients and to compare the prevalence of DE between affected and non-affected eye in HFS patients. Patients and Methods This prospective study included participants with unilateral HFS, who received BTX-A injection as a treatment. The eyes ipsilateral to the spasm side were used as studied eyes and the contralateral eyes were used as controls. The Ocular Surface Disease Index (OSDI) score, tear break-up time (TBUT), corneal fluorescein staining, and Schirmer I test were measured at baseline, 1 and 3 months after BTX-A injection. Fluorescein clearance test (FCT) was evaluated at baseline and at 1 month after BTX-A injection. Results Thirty-one participants (6 males and 25 females; mean age 61±10 years) were included. The prevalence of DE according to the Asia Dry Eye Society was not significantly different between affected (37.93%) and non-affected eyes (27.6%); P=0.083. At baseline, there was no significant difference in TBUT, Schirmer test, basal tear secretion, presence of delayed tear clearance, and presence of reflex tear secretion between affected and non-affected eyes, while significant difference in Oxford scheme grade was observed (P=0.031). OSDI score, TBUT, Oxford scheme grade, and Schirmer test at 1 month (P=0.817, 0.796, 0.534, 0.556), and 3 months (P=0.803, 0.904, 0.936, 0.684) after BTX-A injection did not significantly change from baseline in affected eyes. FCT results were not significantly different between baseline and at 1-month follow-up in both groups. All findings were corresponding in both naïve and long-term botulinum toxin injection groups. Conclusion We found no significant effect of BTX-A on signs and symptoms of DE in patients with HFS. Moreover, there was no significant association between HFS and DE. However, we found significant corneal surface damage in the affected eyes, which emphasized importance of ocular surface evaluation and prompt treatment in HFS patients.

show abstract

Current practice trends for lacrimal gland neurotoxin in the management of epiphora—a BOPSS survey

O’Rourke

Cannon

2021

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm

Cited by 4 publications

References 11 publications

The Effect of Botulinum TOxin Application if Neuro-Ophthalmological Indications on the Results of Schirmer’s Test and Tear Osmolarity

The Effect of Botulinum TOxin Application if Neuro-Ophthalmological Indications on the Results of Schirmer’s Test and Tear Osmolarity

Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A

Current practice trends for lacrimal gland neurotoxin in the management of epiphora—a BOPSS survey

Contact Info

Product

Resources

About